Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy

Abstract

Intravitreal administration of 1.25 mg bevacizumab at the time of cataract surgery was safe and effective in preventing the progression of DR and diabetic maculopathy in patients with cataract and DR.

Effect of intravitreal triamcinolone acetonide injection on central macular thickness in diabetic patients having phacoemulsification

“…Kim et al 21 found no difference in diabetic retinopathy progression 6 months postoperatively between a group receiving sub-Tenon triamcinolone and a control group (P Z .08). Cheema et al 26 evaluated the effect of intravitreal bevacizumab injected during cataract surgery on postoperative diabetic retinopathy progression; progression occurred in 45.45% of eyes in the control group and 11.42% of eyes in the treatment group (P Z .002).…”

A review of clinical trials of anti-VEGF agents for diabetic retinopathy

“…Cheema and colleagues randomized 68 eyes with any type of DR to 1.25 mg bevacizumab at the conclusion of cataract surgery or surgery with no injection [91]. At baseline, 39 eyes had CSME, and all were treated pre-operatively with focal laser.…”

Cataract Surgery in Retina Patients

“…This involves argon laser panretinal photocoagulation as the primary treatment for proliferative retinopathy and focal macular laser for clinically significant macular edema. Additional treatment involves intravitreal injection of vascular endothelial growth factor inhibiting medications and steroids (Cheema et al, 2009;Lam et al, 2005). The patient should also achieve a tight control of systemic blood glucose, and this should be demonstrated in the patient's hemoglobin A1c levels (Suto et al, 2006).…”